MTOR and endometrial carcinoma: In summary, taxol treatment can inhibit the Ishikawa cells and Ishikawa-TAX cells through PI3K/Akt/mTOR signaling pathway, and therefore regulating PI3K/Akt/mTOR pathway may been a promising therapeutic direction for the clinical treatment of drug-resistant endometrial carcinoma.